Literature DB >> 31135951

Effects of dapagliflozin in experimental sepsis model in rats.

Zehra Betül Kingir1, Zarife Nigar Özdemir Kural2, Muhammet Emin Cam3, Ozlem Tugce Cilingir4, Turgut Şekerler5, Feriha Ercan4, Özlem Bingöl Özakpınar5, Derya Ozsavci5, Mesut Sancar1, Betul Okuyan1.   

Abstract

BACKGROUND: The aim of this study was to evaluate the possible protective effects of dapagliflozin in an experimental sepsis model in rats.
METHODS: Saline (1 mL/kg, p.o.) or dapagliflozin (10 mg/kg, p.o.) was administered to Sprague-Dawley rats for 5 days prior to the surgical procedures. Under anesthesia, sepsis was induced by cecal ligation puncture, while sham control groups underwent laparotomy only. Blood urea nitrogen, creatinine, and glucose levels were measured in serum samples and the levels of malondialdehyde (MDA), glutathione (GSH), myeloperoxidase (MPO), tumor necrosis factor alpha, interleukin 1 beta, caspase 8, and caspase 9 were determined in tissue samples (kidney, liver, and lung). Histological evaluation was also performed.
RESULTS: The administration of dapagliflozin in a sepsis model reduced oxidative stress (MDA), increased antioxidant levels (GSH), and reduced inflammation (MPO) in the kidney (p<0.05). Dapagliflozin also decreased oxidative stress (MDA) in lung tissue and decreased inflammation (MPO) in lung and liver tissue (p<0.05). Caspase 8 and 9 levels in kidney, lung, and liver tissue were increased (p<0.05) in the dapagliflozin group compared with the sepsis group. According to the histopathological results, sepsis was moderately improved in renal tissue and slightly attenuated in lung and liver tissue with the administration of dapagliflozin.
CONCLUSION: Dapagliflozin had a preventive effect on sepsis-induced kidney damage, but the protective effect was mild in lung and liver tissue in the present study.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31135951     DOI: 10.5505/tjtes.2018.82826

Source DB:  PubMed          Journal:  Ulus Travma Acil Cerrahi Derg


  6 in total

1.  [Effect of mogroside VI on acute liver injury induced by sepsis in mice and related mechanisms].

Authors:  Hai-Yin Zhou; Cai-Xia Long; Lan Luo; Yan-Ying Chen; Ping-Ping Liu; Zheng-Hui Xiao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-11

2.  Dapagliflozin Guards Against Cadmium-Induced Cardiotoxicity via Modulation of IL6/STAT3 and TLR2/TNFα Signaling Pathways.

Authors:  Marwa M M Refaie; Rehab Ahmed Rifaai; Michael Atef Fawzy; Sayed Shehata
Journal:  Cardiovasc Toxicol       Date:  2022-10-15       Impact factor: 2.755

Review 3.  Anti-Hyperglycemic Agents in the Adjuvant Treatment of Sepsis: Improving Intestinal Barrier Function.

Authors:  Yi-Feng Wang; Jia-Wei Li; Da-Peng Wang; Ke Jin; Jiao-Jie Hui; Hong-Yang Xu
Journal:  Drug Des Devel Ther       Date:  2022-06-04       Impact factor: 4.319

Review 4.  Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?

Authors:  Niki Katsiki; Ele Ferrannini
Journal:  J Diabetes Complications       Date:  2020-08-26       Impact factor: 2.852

5.  Knockdown of phosphoinositide-dependent kinase 1 (PDK1) inhibits fibrosis and inflammation in lipopolysaccharide-induced acute lung injury rat model by attenuating NF-κB/p65 pathway activation.

Authors:  Keke Yang; Boqian Li; Jinghua Chen
Journal:  Ann Transl Med       Date:  2021-11

6.  SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.

Authors:  Li Ma; Rongjun Zou; Wanting Shi; Na Zhou; Shaoxian Chen; Hao Zhou; Xinxin Chen; Yueheng Wu
Journal:  Theranostics       Date:  2022-06-27       Impact factor: 11.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.